Humulin I (Isofano) (Insulin Human (Rdna))

Humulin I (Isofano) is a prescription insulin product that contains recombinant human insulin as its active ingredient. It is supplied in a formulation intended for intramuscular or subcutaneous injection, with the specific strength and dosage form determined by the prescribing information for the European market. As a biosynthetic analogue of endogenous insulin, Humulin I (Isofano) is used to help manage blood glucose levels in patients with diabetes mellitus.

Humulin I (Isofano) is indicated for the treatment of diabetes mellitus, providing basal insulin coverage to control fasting and between‑meal glucose concentrations.

- Type 1 diabetes mellitus requiring basal insulin supplementation. - Type 2 diabetes mellitus when oral agents are insufficient for glycemic control. - Adjunct therapy during pregnancy or lactation under medical supervision, if deemed appropriate. - Management of hyperglycemia in patients undergoing surgery or acute illness. - Replacement therapy for individuals with insulin deficiency due to pancreatic disease. - Use as part of a basal‑bolus insulin regimen combined with rapid‑acting insulin analogues for intensive glucose management. - Adjustment of dose may be required in patients with renal or hepatic impairment to avoid hypoglycemia.

Adverse reactions to Humulin I (Isofano) are generally related to its insulin activity and formulation components.

Common: - Mild hypoglycemia, characterized by shakiness, sweating, or hunger. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy presenting as localized thickening or loss of subcutaneous fat. - Transient weight gain due to fluid retention. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness, especially during rapid glucose changes.

Serious: - Severe hypoglycemia with loss of consciousness, seizures, or coma. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Persistent hyperglycemia indicating possible insulin resistance or dosing error. - Edema or heart failure exacerbation in patients with pre‑existing cardiac disease.

When prescribing Humulin I (Isofano), clinicians should evaluate patient-specific factors and monitor for conditions that may alter insulin requirements or increase risk of adverse events.

- Assess renal and hepatic function, as impairment may prolong insulin action. - Review history of hypoglycemia unawareness and adjust dosing accordingly. - Consider pregnancy, lactation, and pediatric status before initiating therapy. - Monitor weight and signs of fluid retention during long‑term use. - Educate patients on proper injection technique to avoid lipodystrophy. - Adjust dose during periods of illness, surgery, or changes in physical activity.

Humulin I (Isofano) may interact with other agents that affect blood glucose levels or insulin pharmacokinetics.

Avoid: - Concurrent use of other rapid‑acting insulin analogues without dose adjustment. - High‑dose sulfonylureas that markedly increase hypoglycemia risk. - Beta‑blockers that mask hypoglycemia symptoms. - Alpha‑glucosidase inhibitors that may cause gastrointestinal upset and affect insulin absorption.

Use with caution: - Oral antihyperglycemics such as metformin, which may require dose titration. - Corticosteroids that can raise glucose and may necessitate higher insulin doses. - Diuretics, especially thiazides, that can affect electrolyte balance and glucose control. - ACE inhibitors or ARBs, which can alter renal function and thus insulin clearance.